Drug Quantity Management – Per Rx
Ophthalmology – Dry Eye Disease – Lacrisert® (hydroxypropyl cellulose ophthalmic insert)

Table of Contents

Product Identifier(s)

Effective 1/1/23 to 3/21/23: 109937

Effective 3/22/23: 96255

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

This Drug Quantity Management program has been developed to manage potential premature dose escalation of Lacrisert. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per Rx	Home Delivery Quantity per Rx
Lacrisert® (hydroxypropyl cellulose ophthalmic insert)	5 mg ophthalmic insert	60 inserts	180 inserts

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

1. If the individual has not experienced improvement in dry eye symptoms with daily dosing, approve the requested quantity, not to exceed 120 ophthalmic inserts per dispensing at retail and 360 ophthalmic inserts per dispensing at home delivery.
   Note: Examples of dry eye symptoms include conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness and blurred or cloudy vision.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Lacrisert, an ophthalmic insert made of hydroxypropyl cellulose, is indicated for the following uses:[1]

- **Decreased corneal sensitivity**.
- **Exposure keratitis**.
- **Moderate to severe dry eye syndromes**, including keratoconjunctivitis sicca.
- **Recurrent corneal erosions**.

Lacrisert acts to stabilize and thicken the precorneal tear film and prolong the tear film breakup time which is usually accelerated in patients with dry eye states.[1] Lacrisert also acts to lubricate and protect the eye. Lacrisert usually reduces the signs and symptoms resulting from moderate to severe dry eye syndromes, such as conjunctival hyperemia, corneal and conjunctival staining with rose bengal, exudation, itching, burning, foreign body sensation, smarting, photophobia, dryness and blurred or cloudy vision. Progressive visual deterioration which occurs in some patients may be slowed, halted, or sometimes reversed.

Dosing

One Lacrisert ophthalmic insert placed in each eye once daily is usually sufficient to relieve the symptoms associated with moderate to severe dry eye syndromes.[1] Individual patients may require more flexibility in the use of Lacrisert. Some patients may require twice daily use for optimal results. In some patients, several weeks may be required before satisfactory improvement of symptoms is achieved.

Availability

Lacrisert is available as a 5 mg ophthalmic insert supplied in packages containing 60 unit doses, two reusable applicators, and a plastic storage container to store the applicators after use.[1]

References

1. Lacrisert® ophthalmic insert [prescribing information]. Bridgewater, NJ: Bausch & Lomb; October 2019.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	Policy was updated to reflect the existing quantity limits when a product is obtained via home delivery.	08/19/2022